BioXcel Therapeutics News

BioXcel Therapeutics | 8-K: BioXcel Therapeutics Reports First Quarter 2024 Financial Results

May 9 07:17 ET

BioXcel Therapeutics | DEF 14A: Definitive information statements

Apr 29 06:13 ET

BioXcel Therapeutics | DEFA14A: Others

Apr 29 06:13 ET

BioXcel Therapeutics | 8-K: Current report

Apr 22 07:15 ET

BioXcel Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 19 07:03 ET

BioXcel Therapeutics | 8-K: Current report

Apr 10 07:07 ET

BioXcel Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Apr 3 17:00 ET

BioXcel Therapeutics | 8-K: Current report

Mar 25 16:10 ET

BioXcel Therapeutics | 8-K: BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Mar 12 07:17 ET

BioXcel Therapeutics | 8-K: Current report

Feb 14 07:08 ET

BioXcel Therapeutics | 8-K: Current report

Feb 12 12:48 ET

BioXcel Therapeutics | 8-K: Current report

Feb 8 16:58 ET

BioXcel Therapeutics | 8-K: Current report

Feb 8 07:10 ET

BioXcel Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Jan 12 00:00 ET

BioXcel Therapeutics | 8-K: Current report

Dec 18, 2023 07:22 ET

BioXcel Therapeutics | 8-K: Current report

Dec 12, 2023 07:00 ET

BioXcel Therapeutics | 8-K: Current report

Dec 6, 2023 07:00 ET

BioXcel Therapeutics | 8-K: BioXcel Therapeutics Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program, Provides Update on Strategic Financing, and Reports Third Quarter 2023 Financial Results

Nov 14, 2023 07:25 ET

BioXcel Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Nov 2, 2023 06:01 ET

BioXcel Therapeutics | 8-K: Current report

Oct 10, 2023 07:06 ET